Agoracom Blog Home

Posts Tagged ‘#TBI’

Thoughtful Brands $ $PEMTF Announces 10:1 Share Consolidation $ $GBLX $PFE $ $ $ $ $ $

Posted by AGORACOM at 9:09 AM on Monday, April 12th, 2021

Thoughtful Brands, Inc. (CSE:TBI)(FWB:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands“), an eCommerce technology company that researches, develops, markets, and distributes natural health products through various brands in North America and Europe, announces that it intends to consolidate its issued and outstanding common shares (“Shares“) at a ratio of ten (10) pre-consolidated Shares to one (1) post-consolidation Share (the “Consolidation“).

The Company currently has 389,274,701 Shares issued and outstanding. Following the Consolidation there will be approximately 38,927,470 Shares issued and outstanding. No fractional Shares will be issued and any fractions of a Share will be rounded down to the nearest whole number of Shares. The exercise or conversion price and the number of Shares issuable under any of the Company’s outstanding convertible securities will be proportionately adjusted upon Consolidation.

In accordance with the Company’s Articles, the Consolidation will not require the approval of the shareholders.

The Consolidation is subject to the acceptance of the Canadian Securities Exchange.

About Thoughtful Brands Inc.

Thoughtful Brands Inc. is an eCommerce technology company that researches, develops, markets and distributes natural health products through various brands in North America and Europe.


Thoughtful Brands Inc.
Ryan Hoggan

For further information readers are encouraged to contact Joel Shacker, President at +1604-423-4733.

Thoughtful Brands $ Announces Binding Letter of Intent for Reverse-Takeover of Franchise Cannabis $ $GBLX $PFE $ $ $ $ $ $

Posted by AGORACOM at 3:02 PM on Thursday, January 7th, 2021
  • Franchise Cannabis, a leading European medical cannabis company, to complete public listing with strategic expansion into other cannabis markets.
  • Combined company will be well positioned to expand product offerings and distribution channels in the US and Europe.

Thoughtful Brands Inc. (“TBI“) (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) and Franchise Cannabis Corp. (“FCC“) are pleased to announce that they have entered into a binding letter of intent (the “Letter of Intent“), dated January 6, 2021, to consummate a going-public transaction for FCC involving the reverse-takeover of TBI (the “Transaction“).

The Transaction will involve the acquisition of all of the outstanding share capital of FCC by TBI, with the resulting Canadian reporting company being listed on the Canadian Securities Exchange (the “CSE“) under the name “Franchise Cannabis Corp.” (the “Resulting Issuer“). The Transaction is expected to be highly-accretive as both companies look to build on their complementary expertise to grow their respective businesses within the United States and Europe.


Following completion of the Transaction, the Resulting Issuer, through its operating subsidiaries will have two German medical cannabis distribution businesses, a registered cannabis genetics subsidiary in Denmark, cultivation and strategic supply agreements on three continents, and a rapidly growing pharmaceutical distribution business with sales to over 18 countries combined with a high revenue CBD eCommerce platform. In addition, the Resulting Issuer will have a US based CBD extraction facility. Together TBI and FCC remain devoted to building on the growing pharmaceutical distribution platform in Europe while expanding sales channels through its regulated medical cannabis business in Europe and the consumer-focused CBD eCommerce division in North America and expansion to Europe. Management believes the combined companies’ assets are synergistic as they combine expertise and access to the two largest medical cannabis and consumer CBD markets, being the United States and Europe.

Read More:

N.J. Bill to Lessen Jail Time For ‘Magic’ Mushrooms Moves Forward SPONSOR: Thoughtful Brands $TBI $ $GBLX $PFE $ $ $ $ $ $

Posted by AGORACOM at 1:30 PM on Friday, December 11th, 2020

SPONSOR: Thoughtful Brands is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business Thoughtful is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. Click Here For More Info

Lawmakers took a step Monday to reduce penalties for possession of magic mushrooms, a criminal justice reform move that also brings them closer to passing a bill to guide the marijuana industry in New Jersey.

The Assembly Judiciary Committee voted 4-1 with one abstention to advance the bill (A5084). It does not decriminalize psilocybin, but makes possession of up to one ounce a disorderly persons offense rather than a third degree crime. That would drop penalties to a maximum of a $1,000 fine and six months in jail.

Currently, those convicted can face between three and five years in prison.

“It’s much simpler than what appears on the surface,” Assemblyman James Kennedy, D-Union, who sponsored the bill, said during Monday’s hearing. “This is really a downgrading of the charges.”

The move to legalize marijuana has been underway in New Jersey since 2014, but mushrooms only came up last month.

As lawmakers sought to pass a bill that would end arrests for up to six ounces of marijuana, Sen. Nicholas Scutari, D-Union, added a provision to downgrade penalties for psilocybin.

The measure passed the Senate by a vote of 29-4, but the Assembly did not put the amended bill for a full floor vote. The mushrooms came unexpectedly and took away from bill’s goal of ending tens of thousands of annual marijuana arrests that disproportionately involve minorities, some said.

Last week, Kennedy introduced the new bill to separate magic mushrooms. That cleared the way for conversations to resume on both the marijuana decriminalization bill and the bill that will establish rules and regulations for the legal industry.

Lawmakers came to a compromise on the setting rules for a new marijuana industry late Friday, and plan to hold a full vote on the legislation on Dec. 17. The Senate will have to repass its decriminalization bill without the mushroom provision and move on its own version.

New Jersey is not the first state to reconsider its laws on psychedelic mushrooms.

Colorado voted to decriminalize mushrooms in 2019 and Oregon voted this November to legalize their use for medicinal purposes. Several cities in California as well as Washington, D.C., have moved to end arrests over mushroom possession.

Some studies show promising medical benefits of psilocybin to treat depression and anxiety, particularly in cancer patients or others with chronic illnesses, like HIV, Mathew Johnson, a professor of psychiatry at and behavioral sciences at Johns Hopkins Medicine, said during the hearing.

He also said psilocybin carries no risk of an overdose, and the greatest risk comes from people making poor choices while impaired, or from people with certain psychological issues like schizophrenia having adverse reactions.

“When you include it even amongst a large group of legal and illegal drugs…psilocybin mushrooms always falls towards the bottom of the rankings in terms of harms to self or harms to others,” he said.

Some lawmakers remained hesitant.

“I think the bill sends the message to young people in our state that the recreational use and misuse of these substances is really not that big a deal,” said Christopher P. DePhillips, R-Bergen, who voted no on the bill.

Those in favor reiterated that the bill would not legalize or decriminalize the use of psilocybin, but would carry a punishment that more closely fit the crime.

“We open up job opportunities to so many folks who may have done this as a one-off, and then suffered with a life-long third degree indictable conviction,” said Assemblyman Raj Mukherji, D-Hudson.

“I think that public policy will be better served by treating this as a criminal act, but as a disorderly persons offense,” he said.


European Commission Reverses Course, Says CBD Should Not Be Regulated As A Narcotic SPONSOR: Thoughtful Brands $TBI $ $GBLX $PFE $ $ $ $ $ $

Posted by AGORACOM at 12:28 PM on Friday, December 4th, 2020

SPONSOR: Thoughtful Brands is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business Thoughtful is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. Click Here For More Info

  • Makers of CBD foods and supplements no longer face the prospect of a blanket ban in Europe after the European Commission revised its preliminary stance that CBD should be treated as a narcotic.

The Commission sent a statement to the European Industrial Hemp Association and at least one other Novel Food authorization applicant on Wednesday that hemp-derived cannabidiol should not be regulated as a narcotic and therefore can qualify as a food.

The decision comes as a relief to Europe’s hemp industry, reassuring processors and manufacturers that their CBD edible products will not be banned from the EU market.

CBD was included in the EU’s Novel Food Catalogue in January 2019, and since then has required extensive testing and authorization from food safety authorities before it can be included in products and marketed as food across the bloc’s 27 member states.

The European Commission, the executive branch of the European Union, said in July it had stopped reviewing applications for pre-market authorization of CBD products while it decided whether CBD should be regulated as a narcotic.

The Commission cited last month’s Court of Justice ruling, which said CBD derived from the entire hemp plant is not a narcotic under an international drug treaty and is therefore subject to EU law on the free movement of goods among member states.

The Commission’s full statement to Novel Food authorization applicants reads as follows:

“In light of the comments received from applicants and of the recent Court’s judgment in case C-663/184, the Commission has reviewed its preliminary assessment and concludes that cannabidiol should not be considered as drug within the meaning of the United Nations Single Convention on Narcotic Drugs of 1961 in so far as it does not have psychotropic effect. As a consequence, cannabidiol can be qualified as food, provided that also the other conditions of Article 2 of Regulation (EC) No178/2002 are met.”